Trials
2 active
5 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will be treated with oral ifetroban or placebo daily for 365 days”In the company’s words, NCT02682511 on ClinicalTrials.gov
- Tested for
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases and 1 more
- Main trialPhase 2
- “The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).”In the company’s words, NCT02682511 on ClinicalTrials.gov
Other drugs for Scleroderma, Diffuse
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- BelimumabGSK · Phase 3
- PRO-203Prolium Bioscience, Inc · Phase 1/2
- TibulizumabZura Bio Inc · Phase 2
Coming up1
- Jan 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Mar 2026 | Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension | |
| Phase 2Recruiting | Jan 2028 | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 2Completed | 17 Jul 2018 | Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients | |
| Phase 2Completed | 25 Apr 2023 | Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) | |
| Phase 2Completed | 6 Mar 2024 | Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026